Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Indoles/administration & dosage"'
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma
Autor:
Matteo Ramazzotti, Luca Viganò, Mirella Pastore, Maria Letizia Taddei, Monika Lewinska, Javier Cibella, Clelia Peano, Erica Pranzini, Luca Di Tommaso, Elena Sacco, Jessica Iorio, Paola Chiarugi, S. Madiai, Jesper B. Andersen, Chiara Raggi, Ivan Orlandi, B. Piombanti, Giovanni Di Maira, Margherita Correnti, N. Navari, Tiziano Lottini, Annarosa Arcangeli, Giulia Lori, Claudia Campani, Fabio Marra
Publikováno v:
Raggi, C, Taddei, M L, Sacco, E, Navari, N, Correnti, M, Piombanti, B, Pastore, M, Campani, C, Pranzini, E, Iorio, J, Lori, G, Lottini, T, Peano, C, Cibella, J, Lewinska, M, Andersen, J B, di Tommaso, L, Viganò, L, Di Maira, G, Madiai, S, Ramazzotti, M, Orlandi, I, Arcangeli, A, Chiarugi, P & Marra, F 2021, ' Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma ', Journal of Hepatology, vol. 74, no. 6, pp. 1373-1385 . https://doi.org/10.1016/j.jhep.2020.12.031
BACKGROUND & AIMS: Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness in CCA.METHODS: Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef501d3fbda1682299d6ec0832b7ea5
https://doi.org/10.1016/j.jhep.2020.12.031
https://doi.org/10.1016/j.jhep.2020.12.031
Autor:
Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, Karen McCoy, Scott Donaldson, Seth Walker, James Chmiel, Ronald Rubenstein, Deborah K. Froh, Isabel Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor-Cousar, Bruce Barnett, Gary Mueller, Patrick Flume, Floyd Livingston, Nighat Mehdi, Charlotte Teneback, John Welter, Raksha Jain, Dana Kissner, Kapilkumar Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross Carl Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, Damien Downey, Gary Connett, Edward Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, Francois Vermeulen, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof Majoor
Publikováno v:
Lancet, 394(10212), 1940-1948. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221e25362cf07bd88d1d3728962d9a50
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK
Autor:
Daniel Peckham, Paul Whitaker, Anil Mehta, Sinisa Savic, Michael F. McDermott, T. Scambler, J. Holbrook, Christine Etherington, Ian Clifton, Heledd H. Jarosz-Griffiths, Samuel Lara-Reyna, Giulia Spoletini, C. Wong, Fabio Martinon
Publikováno v:
eLife
eLife, Vol 9 (2020)
eLife, vol. 9, pp. e54556
eLife, Vol 9 (2020)
eLife, vol. 9, pp. e54556
Previously, we showed that serum and monocytes from patients with CF exhibit an enhanced NLRP3-inflammasome signature with increased IL-18, IL-1β, caspase-1 activity and ASC speck release (Scambler et al. eLife 2019). Here we show that CFTR modulato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56c3b19820b0ec649de1acb486b5ee6
https://eprints.whiterose.ac.uk/158253/7/elife-54556-v2.pdf
https://eprints.whiterose.ac.uk/158253/7/elife-54556-v2.pdf
Autor:
Anna Geraths, Stefan W. Toennes, Werner Pogoda, Alexander Paulke, Johannes G. Ramaekers, Eef L. Theunissen, Cora Wunder
Publikováno v:
Drug Testing and Analysis, 10(4), 644-650. John Wiley & Sons Inc.
Each year, synthetic cannabinoids occur in high numbers on the illicit drug market, but data on their detectability are rarely available. A pilot study was performed to assess adverse effects of JWH-018, which is one of the oldest and best known synt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b260fe8f22e70ce00f681d9e135bce
https://doi.org/10.1002/dta.2310
https://doi.org/10.1002/dta.2310
Autor:
Werner Pogoda, Alexander Paulke, Stefan W. Toennes, Johannes G. Ramaekers, Anna Geraths, Eef L. Theunissen, Cora Wunder
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis, 150, 162-168. Elsevier
Each year, synthetic cannabinoids are occurring in high numbers on the illicit drug market but data obtained after controlled application are rare. The present study on pharmacokinetics in urine is part of a pilot study on adverse effects of JWH-018,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2124bf6d329f01036396257577807d54
https://doi.org/10.1016/j.jpba.2017.12.016
https://doi.org/10.1016/j.jpba.2017.12.016
Publikováno v:
British Journal of Pharmacology. 175(1):18-28
BACKGROUND AND PURPOSE: Synthetic cannabinoids (often sold as Spice or K2) have become a very popular alternative to cannabis due to their easy access and portrayed safety. Controlled studies on the behavioural effects of synthetic cannabinoids are c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___00893::3dfe19cb7fe41e818c7c542a58519b6c
https://doi.org/10.1111/bph.14066
https://doi.org/10.1111/bph.14066
Autor:
VX17-445-103 Trial Group
Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10691::89138b60eee52c990cd8474204258594
https://dspace.library.uu.nl/handle/1874/391989
https://dspace.library.uu.nl/handle/1874/391989
Autor:
de Weger, Vincent A, de Jonge, Maja, Langenberg, Marlies H G, Schellens, Jan H M, Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles, Goodstal, Samantha, Macé, Sandrine, Deutsch, Eric, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 120(3), 286-293. Nature Publishing Group
British Journal of Cancer, 120(3), 286. Nature Publishing Group
British Journal of Cancer, 120(3), 286-293. Nature Publishing Group
British Journal of Cancer, 120(3), 286. Nature Publishing Group
BACKGROUND: This phase I, open-label, dose-escalation study evaluated the safety, pharmacokinetics and pharmacodynamics of combination therapy with the HDM2 inhibitor SAR405838 and the MEK1/2 inhibitor pimasertib administered orally once daily (QD) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c753c193b29e94b1383adbb0c16bd68
https://dspace.library.uu.nl/handle/1874/391177
https://dspace.library.uu.nl/handle/1874/391177
Autor:
Sabeen Mekan, Philippe Barthélémy, Marc-Oliver Grimm, Bohuslav Melichar, Allen C. Chen, Robert E. Hawkins, David F. McDermott, Christian Kollmannsberger, Brian I. Rini, M. Brent McHenry, Megan Wind-Rotolo, Sergio Bracarda, Nizar M. Tannir, Carlos H. Barrios, Toni K. Choueiri, Camillo Porta, Osvaldo Arén Frontera, Bernard Escudier, Robert J. Motzer, Yoshihiko Tomita, Justin Doan, Howard Gurney, V. Neiman, Frede Donskov, Alain Ravaud, Pamela Salman, Hans J. Hammers, Daniel Castellano, Thomas Powles, Saby George, Elizabeth R. Plimack, Padmanee Sharma
Publikováno v:
CheckMate 214 Investigators 2018, ' Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 378, no. 14, pp. 1277-1290 . https://doi.org/10.1056/NEJMoa1712126
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced rena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be20ad4dc575b4b2b082a5f7053e6c4
https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinoma(9d613da7-a490-4e1e-940a-79cc1309b512).html
https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinoma(9d613da7-a490-4e1e-940a-79cc1309b512).html
Autor:
Theunissen, Eef L, Hutten, Nadia R P W, Mason, Natasha L, Toennes, Stefan W., Kuypers, Kim P C, de Sousa Fernandes Perna, Eliza B, Ramaekers, Johannes G
Publikováno v:
British Journal of Pharmacology, 175(1), 18-28. Wiley
BACKGROUND AND PURPOSE: Synthetic cannabinoids (often sold as Spice or K2) have become a very popular alternative to cannabis due to their easy access and portrayed safety. Controlled studies on the behavioural effects of synthetic cannabinoids are c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::f6f36cd530325c69fc239ce206192c15
https://cris.maastrichtuniversity.nl/en/publications/db4a0475-d3e4-4829-9008-0c5c9c824f22
https://cris.maastrichtuniversity.nl/en/publications/db4a0475-d3e4-4829-9008-0c5c9c824f22